Skip to content

EPS (Diluted) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$0.56+39.8%
Arrowhead Research logo
Arrowhead ResearchARWR
-$0.93-134%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$0.46-7.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$0.03-100%
Scholar Rock logo
Scholar RockSRRK
-$0.83-23.9%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0.50+11.1%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.27B+153%
Enterprise value$2.69B+228%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s EPS (diluted)?
Dyne Therapeutics, Inc. (DYN) reported EPS (diluted) of -$0.73 in Q1 2026.
How has Dyne Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
Dyne Therapeutics, Inc.'s EPS (diluted) increased by 30.5% year-over-year, from -$1.05 to -$0.73.
What is the long-term trend for Dyne Therapeutics, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s EPS (diluted) has grown at a 4.7% compound annual growth rate (CAGR), from -$2.92 to -$3.51.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.